首页|血清miRNAs对SSRIs治疗巩固期停药抑郁症患者复发的影响

血清miRNAs对SSRIs治疗巩固期停药抑郁症患者复发的影响

The effect of serum miRNAs on the recurrence of depression in patients with SSRIs withdrawal during consolidation period

扫码查看
原文链接
  • 维普
  • 万方数据
目的 基于微小核糖核酸-134(miR-134)、微小核糖核酸-16(miR-16)参与抑郁症基因调控过程理论,分析血清中2种因子对5-羟色胺再摄取抑制剂(5-selective serotonin reuptake inhibitors,SSRIs)治疗巩固期内停药的首发抑郁症患者1年期复发风险的影响.方法 选取绍兴市第七人民医院2021年10月-2022年5月5-羟色胺再摄取抑制剂治疗并于巩固期停药的首发抑郁症患者125例.采用Kaplan-Meier生存分析和Cox风险比例回归模型评估血清miR-134、miR-16对停药1年期复发的影响.结果 Kaplan-Meie生存分析结果显示,血清高水平miR-134、miR-16患者"非复发状态"时间为(11.01±0.27)个月和(11.14±0.29)个月,较血清低水平miR-134[(9.32±0.42)个月]、miR-16[(9.59±0.36)个月]患者"非复发状态"时间均显著延长(P＜0.05).Cox分析显示,患者1年期复发的危险因素为抑郁家族史(HR=2.219);保护因素为用药时间延长(HR=0.759)、血清miR-134(HR=0.005)、miR-16(HR＜0.001)水平升高以及联合物理治疗(HR=0.188).结论 血清miR-134、miR-16表达水平升高对巩固期内停药的SSRIs治疗首发抑郁症患者1年期复发具有良好的预防与保护作用.
Objective Based on the theory that microRNA-134(miR-134)and microRNA-16(miR-16)are involved in the gene regulation process of depression,this paper analyzes the effects of two factors in serum on the one-year recur-rence risk of patients with first-episode depression who stopped taking selective serotonin reuptake inhibitors(SSRIs)during the consolidation period.Methods A total of 125 patients with first-episode depression who were treated with 5-hydroxytryptamine reuptake inhibitors and stopped during the consolidation period from October 2021 to May 2022 in Sha-oxing Seventh People's Hospital were selected.Kaplan-Meier survival analysis and Cox proportional hazard regression model were used to evaluate the effect of serum miR-134 and miR-16 on one-year recurrence after withdrawal.Results K-M survival analysis showed that the distribution of the"non-recurrent state"in patients with high serum miR-134 and miR-16 levels was(11.01±0.27)months and(11.14±0.29)months,respectively.This was significantly longer than that in patients with low serum miR-134[(9.32±0.42)months]and miR-16[(9.59±0.36)months,with P＜0.05].Cox analysis showed that family history of depression was the risk factor for one-year recurrence(HR=2.219).The pro-tective factors included prolonged medication time(HR=0.759),elevated serum level of miR-134(HR=0.005),ele-vated level of miR-16(HR＜0.001),and combined physical therapy(HR=0.188).Conclusion The expression levels of serum miR-134 and miR-16 have a good preventive and protective effect on the recurrence of first-episode depression patients after stopping SSRIs for one year in consolidation period.

First-episode depressionSerum microRNA-134Serum microRNA-134Selective serotonin reuptake inhibi-torsConsolidation period withdrawalRecurrence

彭玲、陈莹、陈晶

展开 >

绍兴市第七人民医院焦虑障碍科,浙江绍兴 312000

首发抑郁症 血清微小核糖核酸-134 血清微小核糖核酸-16 5-羟色胺再摄取抑制剂 巩固期停药 复发

浙江省医药卫生科技计划项目绍兴市卫生健康科技计划项目

2023KY12722022KY056

2024

10.16766/j.cnki.issn.1674-4152.003589

中华全科医学
中华预防医学会,安徽省全科医学会

中华全科医学

CSTPCD
影响因子：1.688
ISSN：1674-4152
年,卷(期)：2024.22(7)